Specifically, we showed that the combination of BRAFi with inhibitors of lipogenic enzymes fatty acid synthase (FASN) and 24-dehydrocholesterol reductase (DHCR24) resulted in favorable drug interactions, potentially exploitable for the treatment of BRAFi-resistant melanoma [11,12]. The gene discussed is FASN; the disease is melanoma.